Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05311150
Other study ID # INT/IEC/2021/SPL-1817
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2022
Est. completion date February 15, 2023

Study information

Verified date March 2023
Source Postgraduate Institute of Medical Education and Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the diagnosis of patients with sarcoidosis, there is paucity of literature on the diagnostic yield of the endobronchial biopsies obtained with narrow band imaging (NBI) bronchoscopy. The present study aims to compare the diagnostic yield of endobronchial biopsyperformed under direct narrow band imaging or white light bronchoscopy guidance in suspected sarcoidosis.We hypothesize that the use of NBI will improve the yield of endobronchial biopsy in patients with sarcoidosis.


Description:

The present study will be a randomized controlled trial. It will be performed in the Bronchoscopy suite of the Department of Pulmonary Medicine, PGIMER. Subjects meeting the selection criteria will be randomized 1:1 to undergo EBB under real-time visualization with NBI or white light bronchoscopy. The randomization sequence will be computer generated and the study group allocations will be placed in opaque sealed envelopes. They will be opened just before the performance of the bronchoscopic procedures. Primary outcome:the diagnostic yield of EBB (demonstration of granulomatous inflammation in EBB specimen, in subjects with a final diagnosis of sarcoidosis) Secondary outcomes: 1. Complications related to the procedure (bleeding) 2. Duration of procedure (from the time of entry into the trachea till the completion of the endobronchial biopsy)


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date February 15, 2023
Est. primary completion date January 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age more than 18 years. 2. Clinical presentation and radiological findings (enlarged hilar and or mediastinal lymph nodes >10 mm [short axis], and/or perilymphatic nodules or peribronchovascular thickening on computed tomography [CT] chest) suggesting sarcoidosis. 3. Willing to give informed consent. Exclusion Criteria: 1. Hemodynamic instability (systolic BP <100 mm Hg). 2. Pregnancy. 3. Treatment with systemic glucocorticoids for more than three weeks in the preceding three months. 4. Diagnosis of sarcoidosis possible with another minimally invasive technique such as skin biopsy or peripheral lymph node biopsy.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Narrow band imaging bronchoscopy guided endobronchial biopsy
Examination of the airways will be performed with the narrow band imaging mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
White light bronchscopy guided endobronchial biopsy
Examination of the airways will be performed with the white light bronchoscopy mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.

Locations

Country Name City State
India Postgraduate Institute of Medical Education and Research Chandigarh

Sponsors (1)

Lead Sponsor Collaborator
Postgraduate Institute of Medical Education and Research

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Yield of granulomatous inflammation in endobronchial biopsy in subjects with a final diagnosis of sarcoidosis Diagnostic yield of endobronchial biopsy (demonstration of granulomatous inflammation in EBB specimen, in subjects with a final diagnosis of sarcoidosis) 7 days
Secondary Complications: Bleeding The incidence of bleeding after the endobronchial biopsy 1 day
Secondary Procedure duration Duration of procedure (from the time of entry into the trachea till the completion of the endobronchial biopsy) 1 day
See also
  Status Clinical Trial Phase
Completed NCT04020380 - Azithromycin a Treatment for Pulmonary Sarcoidosis Phase 2
Recruiting NCT03260556 - Pirfenidone for Progressive Fibrotic Sarcoidosis Phase 4
Completed NCT05759221 - Peripheral Airway Biopsy in Sarcoidosis N/A
Completed NCT03336736 - The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis
Completed NCT03140644 - SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis N/A
Completed NCT03793439 - Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis Phase 1
Recruiting NCT04895111 - Endobronchial Ultrasound Strain Elastography in Sarcoidosis
Not yet recruiting NCT05910554 - Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis Phase 2
Recruiting NCT05374447 - Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy N/A
Active, not recruiting NCT04314193 - Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis Phase 4
Completed NCT03727451 - A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis Phase 2
Recruiting NCT05746039 - Feasibility of Semaglutide in Advanced Lung Disease Phase 1/Phase 2
Completed NCT04803617 - Investigation of Pectoralis Muscle Strength in Elderly With Interstitial Lung Disease
Recruiting NCT03145922 - Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis
Completed NCT00279708 - Atorvastatin to Treat Pulmonary Sarcoidosis Phase 2
Recruiting NCT05567133 - Risk Indicators of Sarcoidosis Evolution-Unified Protocol
Not yet recruiting NCT05291468 - the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis N/A
Completed NCT05811962 - The Diagnostic and Prognostic Role of SAA in Intrathoracic Sarcoidosis
Completed NCT03320070 - Acthar Gel in Participants With Pulmonary Sarcoidosis Phase 4
Completed NCT03324503 - A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis N/A